Mortality from breast cancer exceeds 12 000 women annually in the UK, and almost all women die as a result of distant metastases. At presentation, over 95% will have no evidence of metastatic disease on clinical, biochemical and radiological examination (Coombes et al., 1980) . Even after apparently curative surgery, when all the local disease has been eradicated and the axillary nodes show no evidence of histological involvement by tumour, approximately 30% of women relapse with metastases within 5 years (Fisher et al., 1981) . Many of these women will not have received adjuvant chemotherapy as, particularly in premenopausal patients, this is principally given to patients with histological evidence of node involvement.
While several groups have used immunohistological methods to demonstrate axillary node micrometastases that were previously missed on histological examination in a proportion of cases (Trojani et al., 1987) , a review of these studies showed that only 13% of 2400 patients converted from node negative to node positive (Neville et al., 1990) . Recently, we reported that measurements of keratin 19 (K19) mRNA following RT-PCR amplification improved detection of tumour cells in lymph nodes (Schoenfeld et al., 1994) . K19 is universally expressed in breast cancers (Bartek et al., 1985) and is not present in normal lymph nodes (Traweek et al., 1993) .
In this extended study of 125 consecutive patients, we show that this is a more sensitive way to detect micrometastases in lymph nodes.
Materials and methods Patients
All patients gave written, informed consent to this study. Lymph nodes were collected from 125 patients undergoing axillary dissection for breast cancer at Charing Cross Hospital, London, UK, from January 1993 to June 1994. Table I shows the clinical and pathological details. Distant metastases were not detected in any patient by routine staging using isotopic bone scanning, liver ultrasound and chest radiography (Table I) .
Tumour grade (Bloom et al., 1957) Conventional histological examination showed evidence of lymph node involvement in 50/125 (40%) patients: 41% of these had four or more nodes involved. In the lymph nodenegative group, the number of nodes examined using RT-PCR is shown in Table II. As a control group, 28 lymph nodes were collected from 20 patients admitted for a variety of conditions but none of whom had any signs of an epithelial malignancy.
The data were analysed by the chi-square test and the two sample t-test.
RNA extraction, RT-PCR amplification and Southern hybridisation The detailed procedures have been described by our group (Schoenfeld et al., 1994) . Lymph nodes were dissected out taking great care to avoid contamination by using surgical gloves. Each node was then bisected: one half for histological examination and one half for mRNA analysis. Total cellular RNA was extracted using the acid guanidinium-phenolchloroform technique, using RNA,ol (Biogenesis, Bourne- mouth, UK).
DNAase treatment of RNA To remove any contaminating DNA, a sample of the extracted RNA preparation was treated with RNAase-free DNAase 1 (Boehringer Mannheim). To a total volume of 100 M1 containing 12 Mg of RNA was added, 10 mM magnesium chloride, 0.1 mM dithiothreitol, 50 mM Tris-HCl and 10 units of enzyme. The mixture was then incubated at 37°C for 1 h. The enzyme was heat inactivated, and the RNA was ethanol precipitated following phenol-chloroform extraction and was resuspended in water.
Reverse transcription First-strand cDNA was synthesised by using MMLV reverse transcriptase. RNA and 5 x I09 cpm jig-l DNA) using the random primer method, was added and hybridisation was continued for a further 16-20 h. Filters were subsequently washed in 2 x standard saline citrate and 0.5% SDS for 15 min at 42°C with four changes of buffer, and then in 0.1 x standard saline citrate and 0.5% SDS for 15 min at 650C with two changes of buffer, and exposed to Amersham Hyperfilm at -70°C, using intensifying screens. Identity of the K19 PCR product was verified by sequencing several independent isolates using standard methods (data not shown).
Results
RNA from all the histologically involved nodes yielded the expected 460 bp K19 PCR product. Of the 530 histologically negative nodes, 106 (20%) gave a K19 product detectable by Southern hybridisation, indicating the presence of tumour cells in 23/75 (30.6%) of the histologically staged nodenegative patients. Table II shows the number of nodes examined per patient and the number which were positive. Seventeen out of twenty-three patients had more than one positive node: 5/23 patients had four or more nodes positive by PCR. All the normal nodes had amplified GAPDH but displayed no K19 product. When all 125 patients were considered, the presence of the K19 product in lymph nodes was associated with the presence of lymphovascular invasion in the primary (P<0.01), as well as with tumour size (P<0.001) and grade (P=0.01), but not with receptor or menopausal status. In the histologically node-negative patients, there was a weak correlation with tumour grade (P=0.05) and tumour size (P<0.05).
Sections from 33 randomly selected nodes that were negative by histological examination but positive for K19 mRNA expression by RT-PCR were examined for presence of K19 protein by immunohistochemistry; only three cases (9%) were found to have positive staining in morphologically identifiable tumour cells. In one lymph node, only one of two sections examined had three positively stained tumour cells visible; the other two lymph nodes had small clusters of positive tumour cells. Forty-one randomly selected nodes that were negative for both K19 mRNA expression and histology were also negative for immunocytochemistry.
Discussion
Our results show that we can detect mRNA for the epithelial marker K19 in the axillary lymph nodes of almost one-third of patients who have no evidence of tumour involvement on conventional histological examination. This is the expected proportion of patients at risk of early relapse (Fisher et al., 1981) .
The increased detection may be due to our ability to study a more representative proportion of the tissue compared with 1-4 sections. This increases the chance of detecting tumour cells if these are relatively few (Trojani et al., 1987; Neville et al., 1990; Mansi et al., 1991) .
The patients in this study had a preponderance of small carcinomas (Table I) , and thus the test may be particularly relevant for patients with early stage cancers that are now being diagnosed using screening (de Koning et al., 1995) .
The PCR method has the potential for automation and is applicable to other epithelial cancers that express K19 (Bartek et al., 1985) . There was a significant correlation between the presence of PCR-detected micrometastases and tumour size in conventionally node-negative staged patients, but prognostic significance will be determined after longer follow-up time.
Recently, Krismann et al. (1995) reported that a low level of CK-19 mRNA could be found in peripheral blood in normal control subjects. However, these authors used different sets of primaries and did not appear to control for the possibility that, unless specific precautions are taken, small numbers of normal dermal epithelial cells can be aspirated on collecting the blood sample.
Others have used PCR to detect the polymorphic epithelial mucin gene product, but only 15 patients were studied (Nogushi et al., 1994) . Our results have shown that this gene can be expressed in normal lymph nodes (Schoenfeld et al., 1994) .
We conclude that measurement of K19 mRNA in axillary lymph nodes by PCR amplification is a more useful means of detecting micrometastases and may have a role in identifying a group of patients who would benefit from earlier adjuvant chemotherapy and who would otherwise be denied this.
